Mechanism of DNA damage responses induced by exposure to an oligonucleotide homologous to the telomere overhang in melanoma

Oncotarget

Volumn 4, Issue 5, 2013, Pages 761-771

  Pitman, Ryan T ^a   Wojdyla, Luke ^a   Puri, Neelu ^a  

^a UNIVERSITY OF ILLINOIS   (United States)

Author keywords

Melanoma; P53; T oligo; Tankyrase; Telomere; TRF1

Indexed keywords

CASPASE 3; CASPASE 7; CASPASE 9; OLIGONUCLEOTIDE; PROTEIN P53; SMALL INTERFERING RNA; TANKYRASE; TANKYRASE 1; TELOMERIC REPEAT BINDING FACTOR 1; TELOMERIC REPEAT BINDING FACTOR 2; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; DNA DAMAGE; DOWN REGULATION; ENZYME ACTIVATION; ENZYME ACTIVITY; LONG TERM EXPOSURE; MELANOMA; MELANOMA CELL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TELOMERE; UPREGULATION;

EID: 84880302835     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.1047     Document Type: Article

References (46)

1. de Lange T. Protection of mammalian telomeres. Oncogene. 2002; 21(4):532-40.
2. Ruden M and Puri N. Novel anticancer therapeutics targeting telomerase. Cancer Treat Rev. 2013; 39(5):444-56.
3. Puri N, Eller MS, Byers HR, Dykstra S, Kubera J and Gilchrest BA. Telomere-based DNA damage responses: a new approach to melanoma. FASEB J. 2004; 18(12):1373-81.
4. Eller MS, Puri N, Hadshiew IM, Venna SS and Gilchrest BA. Induction of apoptosis by telomere 3' overhangspecific DNA. Exp Cell Res. 2002; 276(2):185-93.
5. Yaar M, Eller MS, Panova I, Kubera J, Wee LH, Cowan KH and Gilchrest BA. Telomeric DNA induces apoptosis and senescence of human breast carcinoma cells. Breast Cancer Res. 2007; 9(1):R13.
6. de Lange T. Shelterin: the protein complex that shapes and safeguards human telomeres. Genes Dev. 2005; 19(18):2100-10.
7. Bilaud T, Brun C, Ancelin K, Koering CE, Laroche T and Gilson E. Telomeric localization of TRF2, a novel human telobox protein. Nat Genet. 1997; 17(2):236-9.
8. Broccoli D, Smogorzewska A, Chong L and de Lange T. Human telomeres contain two distinct Myb-related proteins, TRF1 and TRF2. Nat Genet. 1997; 17(2):231-5.
9. Chong L, van Steensel B, Broccoli D, Erdjument-Bromage H, Hanish J, Tempst P and de Lange T. A human telomeric protein. Science. 1995; 270(5242):1663-7.
10. Celli GB and de Lange T. DNA processing is not required for ATM-mediated telomere damage response after TRF2 deletion. Nat Cell Biol. 2005; 7(7):712-8.
11. Richter T, Saretzki G, Nelson G, Melcher M, Olijslagers S and von Zglinicki T. TRF2 overexpression diminishes repair of telomeric single-strand breaks and accelerates telomere shortening in human fibroblasts. Mech Ageing Dev. 2007; 128(4):340-5.
12. Smith S, Giriat I, Schmitt A and de Lange T. Tankyrase, a poly(ADP-ribose) polymerase at human telomeres. Science. 1998; 282(5393):1484-7.
13. Smith S and de Lange T. Tankyrase promotes telomere elongation in human cells. Curr Biol. 2000; 10(20):1299-302.
14. Chang W, Dynek JN and Smith S. TRF1 is degraded by ubiquitin-mediated proteolysis after release from telomeres. Genes Dev. 2003; 17(11):1328-33.
15. Cook BD, Dynek JN, Chang W, Shostak G and Smith S. Role for the related poly(ADP-Ribose) polymerases tankyrase 1 and 2 at human telomeres. Mol Cell Biol. 2002; 22(1):332-42.
16. Seimiya H and Smith S. The telomeric poly(ADP-ribose) polymerase, tankyrase 1, contains multiple binding sites for telomeric repeat binding factor 1 (TRF1) and a novel acceptor, 182-kDa tankyrase-binding protein (TAB182). J Biol Chem. 2002; 277(16):14116-26.
17. Dregalla RC, Zhou J, Idate RR, Battaglia CL, Liber HL and Bailey SM. Regulatory roles of tankyrase 1 at telomeres and in DNA repair: suppression of T-SCE and stabilization of DNA-PKcs. Aging (Albany NY). 2010; 2(10):691-708.
18. Huang SM, Mishina YM, Liu S, Cheung A, Stegmeier F, Michaud GA, Charlat O, Wiellette E, Zhang Y, Wiessner S, Hild M, Shi X, Wilson CJ, Mickanin C, Myer V, Fazal A, et al. Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling. Nature. 2009; 461(7264):614-20.
19. Eller MS, Li GZ, Firoozabadi R, Puri N and Gilchrest BA. Induction of a p95/Nbs1-mediated S phase checkpoint by telomere 3' overhang specific DNA. FASEB J. 2003; 17(2):152-62.
20. Li GZ, Eller MS, Firoozabadi R and Gilchrest BA. Evidence that exposure of the telomere 3' overhang sequence induces senescence. Proc Natl Acad Sci U S A. 2003; 100(2):527-31.
21. Li GZ, Eller MS, Hanna K and Gilchrest BA. Signaling pathway requirements for induction of senescence by telomere homolog oligonucleotides. Exp Cell Res. 2004; 301(2):189-200.
22. Rankin AM, Sarkar S and Faller DV. Mechanism of T-oligo-induced cell cycle arrest in Mia-PaCa pancreatic cancer cells. J Cell Physiol. 2012; 227(6):2586-94.
23. Longe HO, Romesser PB, Rankin AM, Faller DV, Eller MS, Gilchrest BA and Denis GV. Telomere homolog oligonucleotides induce apoptosis in malignant but not in normal lymphoid cells: mechanism and therapeutic potential. Int J Cancer. 2009; 124(2):473-82.
24. Eller MS, Liao X, Liu S, Hanna K, Backvall H, Opresko PL, Bohr VA and Gilchrest BA. A role for WRN in telomerebased DNA damage responses. Proc Natl Acad Sci U S A. 2006; 103(41):15073-8.
25. Levy C, Khaled M and Fisher DE. MITF: master regulator of melanocyte development and melanoma oncogene. Trends Mol Med. 2006; 12(9):406-14.
26. Polager S and Ginsberg D. p53 and E2f: partners in life and death. Nat Rev Cancer. 2009; 9(10):738-48.
27. He G, Kuang J, Huang Z, Koomen J, Kobayashi R, Khokhar AR and Siddik ZH. Upregulation of p27 and its inhibition of CDK2/cyclin E activity following DNA damage by a novel platinum agent are dependent on the expression of p21. Br J Cancer. 2006; 95(11):1514-24.
28. Gnanasekar M, Thirugnanam S, Zheng G, Chen A and Ramaswamy K. T-oligo induces apoptosis in advanced prostate cancer cells. Oligonucleotides. 2009; 19(3):287-92.
29. Ohashi N, Yaar M, Eller MS, Truzzi F and Gilchrest BA. Features that determine telomere homolog oligonucleotideinduced therapeutic DNA damage-like responses in cancer cells. J Cell Physiol. 2007; 210(3):582-95.
30. Sarkar S and Faller DV. T-oligos inhibit growth and induce apoptosis in human ovarian cancer cells. Oligonucleotides. 2011; 21(1):47-53.
31. Andersen MH, Svane IM, Becker JC and Straten PT. The universal character of the tumor-associated antigen survivin. Clin Cancer Res. 2007; 13(20):5991-4.
32. Grossman D, McNiff JM, Li F and Altieri DC. Expression and targeting of the apoptosis inhibitor, survivin, in human melanoma. J Invest Dermatol. 1999; 113(6):1076-81.
33. Trefzer U, Hofmann M, Reinke S, Guo YJ, Audring H, Spagnoli G and Sterry W. Concordant loss of melanoma differentiation antigens in synchronous and asynchronous melanoma metastases: implications for immunotherapy. Melanoma Res. 2006; 16(2):137-45.
34. Srinivasan R and Wolchok JD. Tumor antigens for cancer immunotherapy: therapeutic potential of xenogeneic DNA vaccines. J Transl Med. 2004; 2(1):12.
35. Eller MS, Yaar M and Gilchrest BA. DNA damage and melanogenesis. Nature. 1994; 372(6505):413-4.
36. Hadshiew IM, Eller MS, Gasparro FP and Gilchrest BA. Stimulation of melanogenesis by DNA oligonucleotides: effect of size, sequence and 5' phosphorylation. J Dermatol Sci. 2001; 25(2):127-38.
37. Pedeux R, Al-Irani N, Marteau C, Pellicier F, Branche R, Ozturk M, Franchi J and Dore JF. Thymidine dinucleotides induce S phase cell cycle arrest in addition to increased melanogenesis in human melanocytes. J Invest Dermatol. 1998; 111(3):472-7.
38. Seimiya H. The telomeric PARP, tankyrases, as targets for cancer therapy. Br J Cancer. 2006; 94(3):341-5.
39. Li G, Tang L, Zhou X, Tron V and Ho V. Chemotherapyinduced apoptosis in melanoma cells is p53 dependent. Melanoma Res. 1998; 8(1):17-23.
40. Karlseder J, Broccoli D, Dai Y, Hardy S and de Lange T. p53-and ATM-dependent apoptosis induced by telomeres lacking TRF2. Science. 1999; 283(5406):1321-5.
41. Rankin AM, Faller DV and Spanjaard RA. Telomerase inhibitors and 'T-oligo' as cancer therapeutics: contrasting molecular mechanisms of cytotoxicity. Anticancer Drugs. 2008; 19(4):329-38.
42. Saretzki G, Sitte N, Merkel U, Wurm RE and von Zglinicki T. Telomere shortening triggers a p53-dependent cell cycle arrest via accumulation of G-rich single stranded DNA fragments. Oncogene. 1999; 18(37):5148-58.
43. Seimiya H, Muramatsu Y, Ohishi T and Tsuruo T. Tankyrase 1 as a target for telomere-directed molecular cancer therapeutics. Cancer Cell. 2005; 7(1):25-37.
44. Riffell JL, Lord CJ and Ashworth A. Tankyrase-targeted therapeutics: expanding opportunities in the PARP family. Nat Rev Drug Discov. 2012; 11(12):923-36.
45. Byers HR, Etoh T, Doherty JR, Sober AJ and Mihm MC, Jr. Cell migration and actin organization in cultured human primary, recurrent cutaneous and metastatic melanoma. Time-lapse and image analysis. Am J Pathol. 1991; 139(2):423-35.
46. Puri N, Ahmed S, Janamanchi V, Tretiakova M, Zumba O, Krausz T, Jagadeeswaran R and Salgia R. c-Met is a potentially new therapeutic target for treatment of human melanoma. Clin Cancer Res. 2007; 13(7):2246-53.